Investors sentiment decreased to 1.19 in 2019 Q2. Its down 0.73, from 1.92 in 2019Q1. It is negative, as 12 investors sold Theravance Biopharma, Inc. shares while 20 reduced holdings. 10 funds opened positions while 28 raised stakes. 34.36 million shares or 3.09% more from 33.32 million shares in 2019Q1 were reported.
Goldman Sachs has 0% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 245,218 shares. Citadel Advsrs Lc reported 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Daiwa Secs Group Inc reported 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). State Street Corp has invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Nomura has 0.02% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH). Swiss National Bank reported 77,342 shares. Manufacturers Life The invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Pnc Finance Ser Grp holds 0% or 56 shares in its portfolio. Northern Tru, Illinois-based fund reported 553,629 shares. Moreover, California Employees Retirement Systems has 0% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 62,715 shares. Barclays Public Limited Co invested 0% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH). Tower Research Llc (Trc) has 1,066 shares. State Of New Jersey Common Pension Fund D invested in 265,459 shares. Zurcher Kantonalbank (Zurich Cantonalbank) reported 2,679 shares. Fosun International Limited has 185,899 shares.
The stock of Theravance Biopharma, Inc. (NASDAQ:TBPH) is a huge mover today! The stock decreased 0.64% or $0.14 during the last trading session, reaching $21.58. About 241,922 shares traded. Theravance Biopharma, Inc. (NASDAQ:TBPH) has declined 10.59% since December 4, 2018 and is downtrending. It has underperformed by 10.59% the S&P500.
The move comes after 9 months negative chart setup for the $1.23 billion company. It was reported on Dec, 4 by Barchart.com. We have $20.93 PT which if reached, will make NASDAQ:TBPH worth $36.75 million less.
Analysts await Theravance Biopharma, Inc. (NASDAQ:TBPH) to report earnings on February, 25. They expect $-1.12 earnings per share, down 21.74 % or $0.20 from last year’s $-0.92 per share. After $-1.05 actual earnings per share reported by Theravance Biopharma, Inc. for the previous quarter, Wall Street now forecasts 6.67 % negative EPS growth.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Coverage
Among 3 analysts covering Theravance Biopharma (NASDAQ:TBPH), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Theravance Biopharma has $55 highest and $1800 lowest target. $32.67’s average target is 51.39% above currents $21.58 stock price. Theravance Biopharma had 7 analyst reports since June 19, 2019 according to SRatingsIntel. The stock has “Buy” rating by Piper Jaffray on Wednesday, June 19. The firm earned “Neutral” rating on Wednesday, November 6 by Robert W. Baird.
More notable recent Theravance Biopharma, Inc. (NASDAQ:TBPH) news were published by: Seekingalpha.com which released: “Key events next week – healthcare – Seeking Alpha” on July 19, 2019, also Nasdaq.com with their article: “Swiss Life Group Reports 9-month Fee Income Growth Of 17% In Local Currency – Nasdaq” published on November 06, 2019, Finance.Yahoo.com published: “Theravance Bio (TBPH) Down 27.7% Since Last Earnings Report: Can It Rebound? – Yahoo Finance” on June 06, 2019. More interesting news about Theravance Biopharma, Inc. (NASDAQ:TBPH) were released by: Streetinsider.com and their article: “Theravance Biopharma (TBPH) Reports First Patient Dosing in Ph. 2 Allergen Challenge Study of TD-8236 (yesterday) – StreetInsider.com” published on December 04, 2019 as well as Prnewswire.com‘s news article titled: “Theravance Biopharma to Report Second Quarter 2019 Financial Results on July 31 – PRNewswire” with publication date: July 25, 2019.
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company has market cap of $1.23 billion. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. It currently has negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.